(±)-4-hydroxy Propranolol (hydrochloride)
(Synonyms: 4-羟基普萘洛尔盐酸盐,(±)-4-hydroxy Propranolol hydrochloride) 目录号 : GC16663
An active metabolite of propranolol
Cas No.:14133-90-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 1.1 μM: inhibits lipid peroxidation in endothelial cells.
(±)-4-hydroxy Propranolol, an active metabolite of propranolol, blocks β1- and β2-adrenergic receptors (β1-ARs, β2-ARs). Also, (±)-4-hydroxy propranolol has antioxidant properties at micromolar concentrations. β1- and β2-ARs, expressed in cardiac myocytes, mediate an increase in contractility by Gs-dependent coupling to adenylyl cyclase.
In vitro: Compared to the control, (±)-4-hydroxy propranolol potently blocked the lipid peroxidation in a concentration-dependent fashion in endothelial cells. When pretreated with (±)-4-hydroxy propranolol at 0.067 to 6.7 μM, the degrees of protection were increased against the glutathione loss in the endothelial cells. Additionally, (±)-4-hydroxy propranolol effectively preserved the loss of cell survival because of the radical stress [1].
In vivo: Rats were injected intravenously with (±)-4-hydroxy propranolol into the femoral vein at 0.1 ml/100 g. (±)-4-hydroxy Propranolol induced an increase in heart rate in a dose-dependent manner in rats depleted of catecholamines, which suggested that (±)-4-hydroxy propranolol had intrinsic sympathomimetic activity. The response of (±)-4-hydroxy propranolol was inhibited when rats were pretreated with 0.5 mg/kg propranolol [2].
References:
[1]. Mak, I. Potent Antioxidant Properties of 4-Hydroxyl-propranolol. Journal of Pharmacology and Experimental Therapeutics. 2003; 308(1): 85-90.
[2]. FITZGERALD, J., & O'DONNELL, S. Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. British Journal of Pharmacology. 1971; 43(1): 222-235.
| Cas No. | 14133-90-5 | SDF | |
| 别名 | 4-羟基普萘洛尔盐酸盐,(±)-4-hydroxy Propranolol hydrochloride | ||
| 化学名 | 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-1-naphthalenol, monohydrochloride | ||
| Canonical SMILES | OC1=CC=C(OCC(O)CNC(C)C)C2=C1C=CC=C2.Cl | ||
| 分子式 | C16H21NO3 • HCl | 分子量 | 311.8 |
| 溶解度 | ≤30mg/ml in ethanol;50mg/ml in DMSO;30mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2072 mL | 16.0359 mL | 32.0718 mL |
| 5 mM | 0.6414 mL | 3.2072 mL | 6.4144 mL |
| 10 mM | 0.3207 mL | 1.6036 mL | 3.2072 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。